Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen

Bone Marrow Transplantation

Volumn 28, Issue 3, 2001, Pages 243-249

  Morecki, S ^a   Gelfand, Y ^a   Nagler, A ^a   Or, R ^a   Naparstek, E ^a   Varadi, G ^a   Engelhard, D ^a   Akerstein, A ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic bone marrow transplantation (BMT); Immune response; Non myeloablative stem cell transplantation (NST)

Indexed keywords

BIOLOGICAL MARKER; BUFFER; BUSULFAN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYELOABLATIVE AGENT; OKT 4; OKT 8; PHOSPHATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOLOGICAL PARAMETERS; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MITOGENICITY; PRIORITY JOURNAL; SIDE EFFECT; SUBSTITUTION THERAPY; TREATMENT PLANNING;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM; INFECTION; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 0034892187     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703118     Document Type: Article

References (42)

1. Kettering Award lecture. The role of marrow transplantation in the eradication of malignant disease
2. Allogeneic bone marrow transplantation: Current status and future directions
3. Graft-versus-leukemia reactions after bone marrow transplantation
4. Bone marrow transplantation in patients with thalassemia
5. Immune reconstitution after bone marrow transplantation
6. Defective T-cell stimulatory pathways in patients after allogeneic bone marrow transplantation (BMT) in man
7. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation
8. Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation
9. Immunological recovery in 48 patients following syngeneic marrow transplantation for hematological malignancy
10. Immunologic reconstitution after human marrow grafting
11. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
12. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia
13. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL
14. Management of follicular lymphoma
15. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
16. Isolation of leukocytes from human blood
17. The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells
18. Linear regression and correlation
19. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2
20. Long-term observation of immunologic reconstitution after allogeneic bone marrow transplantation: Differences in recovery among functional T cell subsets
21. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation
22. Immunologic reconstitution of peripheral blood lymphocytes in patients treated by bone marrow transplantation
23. B lymphocyte regeneration in marrow and blood after autologous bone marrow transplantation: Increased numbers of B cells carrying activation and progression markers
24. IgG subclass levels and immune reconstitution after T cell-depleted allogeneic bone marrow transplantation
25. The reappearance of 10 differentiation antigens on peripheral blood lymphocytes after allogeneic bone marrow transplantation
26. Immune reconstitution after BMT in children
27. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia
28. Peripheral blood lymphocyte subsets after allogeneic bone marrow transplantation: Reconstitution and correlation with the occurrence of acute graft-versus-host disease
29. Recovery of natural cytotoxicity after bone marrow transplantation
30. Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation
31. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation
32. Imbalances within the peripheral blood T-helper (CD4+) and T-suppressor (CD8+) cell populations in the reconstitution phase after human bone marrow transplantation
33. Constitutive and mitogen-stimulated cytokine mRNA expression by peripheral blood mononuclear cells from most autologous and allogeneic bone marrow transplant recipients is intact
34. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation
35. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice. Long-term survival of allogeneic bone marrow and skin grafts
36. Transplantation tolerance in adult rats using total lymphoid irradiation (TLI): Permanent survival of skin, heart and marrow allografts
37. Overview: Transplantation tolerance across major histocompatibility barriers after total lymphoid irradiation
38. Total lymphoid irradiation (TLI)
39. Permanent and specific transplantation tolerance induced by a non-myeloablative treatment to a wide variety of allogeneic tissues
40. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marow leads to specific acceptance of allografts and xenografts
41. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen
42. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning